HPV Testing and Pap Test Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028 Segmented Test Type (HPV Test, Pap Test, Co-testing), By Application (Cervical Cancer Screening Test, Head and Neck Cancer Screening Test, Other Applications), By End User (Hospitals/Clinics, Diagnostic Centers, Point-of-Care/Self-sampling) By Region and Competition

Market Overview

Key Market Drivers

Rising Cervical Cancer Incidence and Mortality Rates

Advancements in Diagnostic Technologies

Growing Awareness and Education

Key Market Challenges

Limited Access to Healthcare Services

Vaccine Hesitancy

Socioeconomic Disparities

Key Market Trends

Rapid Adoption of HPV DNA Testing

Liquid-Based Cytology for Pap Smears

Segmental Insights

Test Type Insights

Application Insights

Regional Insights

Recent Developments

• In June 2022, Roche announced the introduction of an HPV self-samplingsolution in nations that recognise the CE mark. A patient can now quietlyobtain a sample for HPV screening thanks to this new solution. On a Rochemolecular device, the clinically verified vaginal sample is examined with theRoche Cobas HPV test.
• In May 2021, According to the IVD directive 98/79/EC, Becton, Dickinson,and Company declared that the first self-collection claim for HPV screening inthe industry has received CE marking. With the help of a BD diluent tube andthe BD Onclarity HPV Assay on either the BD Viper LT or the BD COR System, thenew claim enables labs and facilities to process self-collected samples.

Key Market Players

• Arbor Vita Corporation
• DanaherCorporation (Cepheid)
• SeegeneInc.
• Becton,Dickinson and Company
• TruScreen
• AbbottLaboratories
• HologicInc.
• QiagenNV
• F.Hoffmann-La Roche AG
• OncoHealthCorporation